elunetirom   Click here for help

GtoPdb Ligand ID: 12973

Synonyms: ABX-002 | ABX002 | compound 1 [WO2022236133A1] | MA-JD-21 | MA-JD21
Compound class: Synthetic organic
Comment: ABX-002 is an orally delivered, potent CNS-directed thyroid hormone receptor beta (TRβ) agonist. Structurally ABX-002 is an amide prodrug (that can penetrate the blood-brain barrier) which is cleaved by fatty acid amide hydrolase (FAAH) to the active metabolite ABX-002A [1]. It is proposed to promote the oligodendrocyte differentiating and myelinating/remyelinating activites of thyroid hormone in the brain, whilst minimising the peripherally-driven side effects of synthetic thyroid hormone, and was originally intended for the treatment of demyelinating neurodegenerative CNS disorders [1]. ABX-002 is more recently being investigated as a potentiator of serotoninergic (5-HT) antidepressants in the brains of patients with major depressive disorder.
The chemical structure of ABX-002 is identical to that for the INN elunetirom (proposed list 132, Feb. 2025).
2D Structure
Click here for help

2D Structure

An image of the ligand's 2D structure. For small molecules with SMILES these are drawn using the NCI/CADD Chemical Identifier Resolver. Click on the image to access the chemical structure search tool with the ligand pre-loaded in the structure editor. For other types of ligands, e.g. longer nucleotides and peptides, a manually drawn representation of the molecule may be provided.

✖
Click here for structure editor
Physico-chemical Properties
Click here for help

Physico-chemical Properties

Calculated molecular properties are available for small molecules and natural products (not peptides). Properties were generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/). All properties were selected to enable the prediction of the Lipinski Rule-of-Five profile or ‘druglikeness’ for each ligand. For more info on each category see the help pages.

✖
Hydrogen bond acceptors 4
Hydrogen bond donors 2
Rotatable bonds 7
Topological polar surface area 58.56
Molecular weight 382.28
XLogP 3.12
No. Lipinski's rules broken 0

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)
SMILES / InChI / InChIKey
Click here for help

SMILES / InChI / InChIKey

SMILES (Simplified Molecular Input Line Entry Specification) A specification for unambiguously describing the structure of chemical molecules using short ASCII strings. Canonical SMILES specify a unique representation of the 2D structure without chiral or isotopic specifications. Isomeric SMILES include chiral specification and isotopes.

Standard InChI (IUPAC International Chemical Identifier) and InChIKey InChI is a non-proprietary, standard, textual identifier for chemical substances designed to facilitate linking of information and database searching. An InChIKey is a simplified version of a full InChI, designed for easier web searching.

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

✖
Canonical SMILES CC(C)C1=CC(=CC=C1O)CC2=C(C=C(C=C2Cl)OCC(=O)NC)Cl
Isomeric SMILES CC(C)C1=C(C=CC(=C1)CC2=C(C=C(C=C2Cl)OCC(=O)NC)Cl)O
InChI InChI=1S/C19H21Cl2NO3/c1-11(2)14-6-12(4-5-18(14)23)7-15-16(20)8-13(9-17(15)21)25-10-19(24)22-3/h4-6,8-9,11,23H,7,10H2,1-3H3,(H,22,24)
InChI Key CQELSEDWYWTMDG-UHFFFAOYSA-N

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)
No information available.
Summary of Clinical Use Click here for help
ABX-002 has advanced into clinical development.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT05528315 SAD/MAD of ABX-002-1902 Investigating the Safety, Pharmacokinetics/Pharmacodynamics of in Healthy Subjects Phase 1 Interventional Autobahn Therapeutics, Inc.